Department of Defense
Also known as: Armed Forces Institute of Regenerative Medicine | Armed Forces Medical College | Armed Forces Research Institute of Medical Sciences (AFRIMS) | Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand | Armed Services Blood Program | Congressionally Directed Medical Research Programs | DARPA (United States Department of Defense) | Department of Defense Congressionally Directed Medical Research Program | Immunization HealthCare Division, Defense Health Agency | Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) | Steadman Philippon Research Institute | The Steadman Clinic | The United States Department of Defense USAMRDC | United States Department of Defense | United States Department of Defense (DOD) | US Defense Health Program | US Department of Defense - Defense Threat Reduction Agency
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1999Last known activity
May 31, 2026
Timeline
1940s
- Sep 18, 1947
Department of Defense— Founded
Drugs by trial phase (395 distinct, 414 trials)
Phase 4 (34 own, 0 via acquisition)
Phase 3 (35 own, 0 via acquisition)
Phase 2 (198 own, 0 via acquisition)
Phase 1 (97 own, 0 via acquisition)
Other trials (31 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Acute Pain
- Acute Radiation Syndrome
- Adenocarcinoma
- Adenoma
- Alcohol Drinking
- Alcoholism
- Altitude Sickness
- Amputation, Traumatic
- Anorexia
- Anorexia Nervosa
- Anxiety Disorders
- Apnea
- Arthritis
- Asperger Syndrome
- Autism Spectrum Disorder
- Autistic Disorder
- Back Pain
- Bacterial Infections
- Bone Diseases
- Bone Resorption
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Carcinoma In Situ
- Breast Neoplasms
- Breast Neoplasms, Male
- Burns
- Candidiasis
- Carcinoma
- Carcinoma, Ductal
- Carcinoma in Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Lobular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Charcot-Marie-Tooth Disease
- Child Development Disorders, Pervasive
- Chronic Pain
- Cicatrix
- Cicatrix, Hypertrophic
- Cognitive Dysfunction
- Combat Disorders
- Communicable Diseases
- Contracture
- Corneal Neovascularization
- Coronary Artery Disease
- Dengue
- Depression
- Developmental Disabilities
- Diabetes Insipidus
- Disease
- Dysentery, Bacillary
- Dyssomnias
- Edema
- Encephalitis
- Encephalomyelitis, Equine
- Epilepsy
- Epilepsy, Post-Traumatic
- Epistaxis
- Fatigue
- Fecal Incontinence
- Femoral Fractures
- Fever
- Fibrosis
- Fractures, Bone
- Fractures, Stress
- Glomerulosclerosis, Focal Segmental
- Hand Injuries
- Headache
- Head and Neck Neoplasms
- Hemorrhage
- Hemorrhagic Fever, Ebola
- Hemorrhagic Fevers, Viral
- Hereditary Sensory and Motor Neuropathy
- HIV Infections
- Hyperplasia
- Hypertrophy
- Hypothermia
- Infections
- Inflammation
- Influenza, Human
- Intracranial Hypertension
- Ischemia
- Joint Dislocations
- Kidney Diseases
- Language Disorders
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Cirrhosis
- Low Back Pain
- Lung Diseases
- Lung Neoplasms
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Discoid
- Lupus Erythematosus, Systemic
Recent trials (50)
- NCT07166393CollaboratorPhase 2/Phase 3May 31, 2026
- NCT07212998CollaboratorPhase 3Apr 30, 2026
- NCT07187011CollaboratorPhase 2Apr 1, 2026
- NCT07221942CollaboratorPhase 2Jan 31, 2026
- NCT07288151CollaboratorPhase 2Jan 31, 2026
- NCT07251491CollaboratorPhase 1/Phase 2Jan 1, 2026
- NCT07090148CollaboratorPhase 1Dec 31, 2025
- NCT07076498CollaboratorPhase 1Dec 1, 2025
- NCT07091279CollaboratorPhase 2Nov 22, 2025
- NCT06889168CollaboratorPhase 1Oct 31, 2025
- NCT07217379CollaboratorPhase 1Oct 31, 2025
- NCT06964009CollaboratorPhase 1Sep 22, 2025
- NCT07207408CollaboratorPhase 2Sep 11, 2025
- NCT06943404CollaboratorPhase 2Aug 29, 2025
- NCT06961084CollaboratorPhase 2Jul 14, 2025
Details
- Founded
- Arlington, VA, US Sep 18, 1947
- Last known activity
- May 31, 2026